NIVF NewGenIvf Group Ltd Annual reports only
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1981662
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-13.0%
TTM net income YoY1,983.1%
TTM EPS YoY100.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR178.2%
Margins
Gross margin20.2%
Operating margin-226.9%
Net margin209.0%
FCF margin-234.0%
EBITDA margin-223.0%
Returns
ROE77.2%
ROA54.4%
ROIC (approx.)-88.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.12x
Interest coverage-17.40x
Cash quality & payout
Operating cash flow / net income-1.11x
Accruals ratio114.6%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.73M | $5.43M |
| Cost of revenue | $3.77M | $3.61M |
| Gross profit | $955,846 | $1.83M |
| SG&A expense | $10.49M | $2.78M |
| Operating income | -$10.73M | -$1.16M |
| Interest expense | $616,423 | $765,177 |
| Pretax income | $9.73M | -$960,807 |
| Income tax | — | -$486,706 |
| Net income | $9.88M | -$524,643 |
| EBITDA | -$10.54M | -$1.14M |
| EPS (basic) | 214.73 | -4,408.76 |
| EPS (diluted) | 3.04 | -4,408.76 |
| Weighted avg. shares (diluted) | 3.25M | 119 |
| Banking | ||
| Provision for credit losses | — | $17,818 |
| Balance sheet | ||
| Cash & equivalents | $758,621 | $457,740 |
| Receivables | $166,531 | $49,245 |
| Inventory | $335,360 | $80,813 |
| Current assets | $7.38M | $3.17M |
| PP&E, net | $1.79M | $273,096 |
| Intangibles | $21.42M | — |
| Total assets | $32.72M | $3.58M |
| Current liabilities | $2.37M | $2.72M |
| Total liabilities | $6.74M | $5.06M |
| Shareholders' equity | $26.63M | -$1.05M |
| Shares outstanding | 240,622 | 380 |
| Cash flow statement | ||
| Operating cash flow | -$10.93M | -$8.26M |
| Capital expenditure | $135,025 | $53,045 |
| Free cash flow | -$11.06M | -$8.32M |
| Investing cash flow | -$7.56M | -$53,045 |
| Financing cash flow | $18.99M | $8.68M |
| Depreciation & amortization | $188,109 | $19,502 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.